These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 32268883)

  • 21. What regulates hepcidin in poly-transfused β-Thalassemia Major: erythroid drive or store drive?
    Chauhan R; Sharma S; Chandra J
    Indian J Pathol Microbiol; 2014; 57(1):39-42. PubMed ID: 24739829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches.
    Schmidt PJ; Fleming MD
    Hematol Oncol Clin North Am; 2014 Apr; 28(2):387-401. PubMed ID: 24589273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic Correlation of HBB, HFE and HAMP Genes to Endocrinal Complications in Egyptian Beta Thalassemia Major Patients.
    Sokkar MF; Hamdy M; Taher MB; El-Sayed H; Bayomi EA; Amr KS; El-Kamah GY
    Biochem Genet; 2024 Jul; ():. PubMed ID: 38954212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepcidin in beta-thalassemia.
    Nemeth E
    Ann N Y Acad Sci; 2010 Aug; 1202():31-5. PubMed ID: 20712769
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liver expression of hepcidin and other iron genes in two mouse models of beta-thalassemia.
    De Franceschi L; Daraio F; Filippini A; Carturan S; Muchitsch EM; Roetto A; Camaschella C
    Haematologica; 2006 Oct; 91(10):1336-42. PubMed ID: 17018382
    [TBL] [Abstract][Full Text] [Related]  

  • 27. mRNA expression of iron regulatory genes in beta-thalassemia intermedia and beta-thalassemia major mouse models.
    Weizer-Stern O; Adamsky K; Amariglio N; Rachmilewitz E; Breda L; Rivella S; Rechavi G
    Am J Hematol; 2006 Jul; 81(7):479-83. PubMed ID: 16755567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Iron-chelating effect of silymarin in patients with β-thalassemia major: A crossover randomised control trial.
    Darvishi-Khezri H; Salehifar E; Kosaryan M; Karami H; Mahdavi M; Alipour A; Aliasgharian A
    Phytother Res; 2018 Mar; 32(3):496-503. PubMed ID: 29235162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice.
    Gardenghi S; Ramos P; Marongiu MF; Melchiori L; Breda L; Guy E; Muirhead K; Rao N; Roy CN; Andrews NC; Nemeth E; Follenzi A; An X; Mohandas N; Ginzburg Y; Rachmilewitz EA; Giardina PJ; Grady RW; Rivella S
    J Clin Invest; 2010 Dec; 120(12):4466-77. PubMed ID: 21099112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An investigation of the effects of curcumin on iron overload, hepcidin level, and liver function in β-thalassemia major patients: A double-blind randomized controlled clinical trial.
    Mohammadi E; Tamaddoni A; Qujeq D; Nasseri E; Zayeri F; Zand H; Gholami M; Mir SM
    Phytother Res; 2018 Sep; 32(9):1828-1835. PubMed ID: 29806132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of Single-Nucleotide Polymorphism in the Hepcidin Promoter Gene with Susceptibility to Extrapulmonary Tuberculosis.
    Liang L; Liu H; Yue J; Liu LR; Han M; Luo LL; Zhao YL; Xiao H
    Genet Test Mol Biomarkers; 2017 Jun; 21(6):351-356. PubMed ID: 28530443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Curative effects and safety of deferasirox in treatment of iron overload in children with β-thalassemia major].
    Gao HY; Li Q; Chen JJ; Chen GF; Li CG
    Zhongguo Dang Dai Er Ke Za Zhi; 2011 Jul; 13(7):531-4. PubMed ID: 21752315
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deferasirox effectively decreases iron burden in patients with double heterozygous HbS/β-thalassemia.
    Voskaridou E; Plata E; Douskou M; Sioni A; Mpoutou E; Christoulas D; Dimopoulou M; Terpos E
    Ann Hematol; 2011 Jan; 90(1):11-5. PubMed ID: 20661572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepcidin expression from monocyte of splenectomized and non-splenectomized patients with HbE-β-thalassemia.
    Pratummo K; Jetsrisuparb A; Fucharoen S; Tripatara A
    Hematology; 2014 Apr; 19(3):175-80. PubMed ID: 23905873
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with β-thalassemia major: a longitudinal study.
    Pasricha SR; Frazer DM; Bowden DK; Anderson GJ
    Blood; 2013 Jul; 122(1):124-33. PubMed ID: 23656728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Iron overload and iron-chelating therapy in hemoglobin E-beta thalassemia.
    Olivieri NF; De Silva S; Premawardena A; Sharma S; Viens AM; Taylor CM; Brittenham GM; Weatherall DJ
    J Pediatr Hematol Oncol; 2000; 22(6):593-7. PubMed ID: 11132236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SLN124, a GalNac-siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron-overload in a mouse model of β-thalassaemia.
    Vadolas J; Ng GZ; Kysenius K; Crouch PJ; Dames S; Eisermann M; Nualkaew T; Vilcassim S; Schaeper U; Grigoriadis G
    Br J Haematol; 2021 Jul; 194(1):200-210. PubMed ID: 33942901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the Association of Transferrin Receptor Type 2 Gene Mutation (Y250X) with Iron Overload in Major β- Thalassemia.
    Abdulmalek Jaafar J; Al-Rashedi NAM
    Arch Razi Inst; 2021 Nov; 76(5):1551-1554. PubMed ID: 35355750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relation of Serum Ferritin Level with Serum Hepcidin and Fucose Levels in Children with β-Thalassemia Major.
    Al-Zuhairy SH; Darweesh MA; Othman MA
    Hemoglobin; 2021 Jan; 45(1):69-73. PubMed ID: 33733981
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in β-thalassemia major patients receiving desferrioxamine.
    Moayedi B; Gharagozloo M; Esmaeil N; Maracy MR; Hoorfar H; Jalaeikar M
    Eur J Haematol; 2013 Mar; 90(3):202-9. PubMed ID: 23278124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.